Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350877 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL95738 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2352413 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2351564 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11753530 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL27965 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11032494 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11518271 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL8846723 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL95500 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| EP-4182296-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | Sanofi Pasteur (FR) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022013439-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2022-01-20 | — | — | WO | disclosed |
| CN-107011132-A | Aromatic compound containing side chain | 味之素株式会社 | 2017-08-04 | — | — | CN | disclosed |
| CN-107011131-A | Aromatic compound containing side chain | 味之素株式会社 | 2017-08-04 | — | — | CN | disclosed |
| CN-106977567-A | Protect oligonucleotides in base portion | 味之素株式会社 | 2017-07-25 | — | — | CN | disclosed |
| CN-104114569-B | Oligonucleotide with protected base moiety | 味之素株式会社 | 2017-04-26 | — | — | CN | disclosed |
| CN-103080058-B | Aromatic compound containing branched chain | 味之素株式会社 | 2017-04-12 | — | — | CN | disclosed |
| CN-106220482-A | Aromatic compound containing side chain | 味之素株式会社 | 2016-12-14 | — | — | CN | disclosed |
| CN-104114569-A | Oligonucleotide with protected base moiety | AJINOMOTO KK | 2014-10-22 | — | — | CN | disclosed |
| CN-103080058-A | Aromatic compound containing branched chain | AJINOMOTO KK | 2013-05-01 | — | — | CN | disclosed |
| US-8088395-B2 | Phytol derived immunoadjuvants and their use in vaccine formulations | INDIANA STATE UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088395-B2 | Phytol derived immunoadjuvants and their use in vaccine formulations | INDIANA STATE UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | MTTP, CETP, LNPEP | LMNA 11/4885BLM 1645/4885PTPN1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.